UroCCR Database: French Research Network for Kidney Cancer -UroCCR
NCT ID: NCT03293563
Last Updated: 2025-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
30000 participants
OBSERVATIONAL
2011-12-31
2040-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
More than a registry, UroCCR is a collaborative network of clinical and research professionals using a shared, evolving tool that supports rapid implementation of studies and fosters active knowledge generation. Unlike retrospective registries or sample-centred biobanks, UroCCR offers prospective, patient-focused inclusion and a wide scope of investigation-from translational and technological research to clinical evaluation and social sciences. It also supports multiple ancillary studies, including retrospective analyses and prospective clinical or observational trials, and operates under a structured governance system with recognised national and international labels.
By combining a rigorously structured, multicentre dataset with linkage to the French national health data system (SNDS), the platform uniquely unites detailed clinical annotation with population-wide coverage, creating a high-value environment for advancing kidney cancer research and care.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Variations of the Blood Pressure After Nephrectomy for Renal Cancer (VAPANCR)
NCT03218319
Diuresis, Functional Bladder Capacity and LUTS in CKD and ESRD Patients.
NCT04622215
Factors Influencing Risk of Progression of Chronic Kidney Disease
NCT03954470
Prognostic Value of a Multidimensional Assessment for Survival in Elderly Patients With CKD 4B/5
NCT06825234
Identification of Cardiovascular Risk Factors Linked to Renal Failure Progression
NCT00608998
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
With over 21,000 cases collected from 58 centres across France, UroCCR is now one of the largest national databases dedicated to kidney cancer worldwide. The registry captures detailed clinical parameters, treatments and outcomes, complemented by patient-reported measures and socioeconomic data. Because management practices within UroCCR follow the recommendations of the French Association of Urology (AFU), the dataset closely reflects real-world practice and provides a reliable basis for comparison with national and European guidelines. Moreover, patient data can be reused across numerous studies, allowing researchers to explore multiple scientific questions without requiring new enrolments for each project.
A distinctive strength of UroCCR is its integration of multiple research dimensions. Beyond clinical outcomes, it evaluates quality of life and the social and economic impact of kidney cancer. The registry is linked to annotated biobanking and national medico-administrative datasets, enabling translational studies and health services research. Additionally, UroCCR supports multiple ancillary studies, both retrospective analyses based on real-world data and prospective studies including randomised clinical trials or observational cohorts.
The project benefits from robust governance structures, ensuring standardised procedures, data quality, and ethical oversight. It has also received various national and international labels, recognising its methodological rigour and excellence in research infrastructure.
Digital innovations developed within the network, such as UroConnect® for perioperative monitoring and UroPredict machine learning models for recurrence and survival prediction, highlight its commitment to advancing care through new technologies.
At the national level, projects such as CARARE are developing personalised treatment strategies, including a molecular tumour board for non-clear cell RCC. Internationally, UroCCR is strengthening collaboration through partnerships with the European Association of Urology and the European Robotic Urology Section, contributing to harmonised data collection and large-scale multicentre research.
Ultimately, UroCCR functions as a dynamic research platform that unites clinicians, researchers, and patients around a shared infrastructure. By combining detailed clinical data with translational research, digital health tools, structured governance, recognised labels, and international partnerships, it aims to generate increasingly precise insights into RCC and to support the development of more effective, personalised treatment strategies in France and worldwide.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients
Adult patients with kidney cancer
Radical nephrectomy versus partial nephrectomy (according surgeon judgement)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Radical nephrectomy versus partial nephrectomy (according surgeon judgement)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with no opposition to collection of its data for the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Bordeaux
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Christophe BERNHARD, PHU
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Bordeaux
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Universitaire de Bruxelles
Brussels, , Belgium
CHU Angers
Angers, , France
CHU Bordeaux
Bordeaux, , France
Clinique TIVOLI-DUCOS
Bordeaux, , France
Polyclinique Médipôle Saint-Roch_Cabestany
Cabestany, , France
CHU Caen
Caen, , France
CHU de Clermont-Ferrand
Clermont-Ferrand, , France
Ch Sud Francilien
Corbeil-Essonnes, , France
CHU Henri Mondor - APHP
Créteil, , France
CHU de Dijon et CLCC Dijon
Dijon, , France
CH du Sud Seine et Marne
Fontainebleau, , France
Centre Hospitalier Départemental de Vendée
La Roche-sur-Yon, , France
CHU Grenoble
La Tronche, , France
Pôle Santé Sud
Le Mans, , France
CH Libourne
Libourne, , France
CHRU Lille - Centre Oscar Lambret
Lille, , France
Hôpital privé La Louvière
Lille, , France
CHU Limoges
Limoges, , France
HCL Lyon
Lyon, , France
APH Marseille
Marseille, , France
Institut Paoli-Calmette
Marseille, , France
Centre Hospitalier d' Annecy Genevois
Metz, , France
CH Mont de Marsan
Mont-de-Marsan, , France
Clinique du Pont de Chaume
Montauban, , France
CHRU de Nancy
Nancy, , France
CHU de Nantes
Nantes, , France
CHU de Nice
Nice, , France
Clinique Saint George
Nice, , France
CHU de Nîmes
Nîmes, , France
CHU d'Orléans
Orléans, , France
CHU Kremlin Bicêtre - APHP
Paris, , France
CH St Joseph
Paris, , France
Hôpital Européen Georges Pompidou - APHP
Paris, , France
CHU Tenon - APHP
Paris, , France
Hôpital Bichat -APHP
Paris, , France
Hôpital Cochin Port-Royal - APHP
Paris, , France
Hôpital Pitié Salpétrière - APHP
Paris, , France
Institut Mutualiste Montsouris
Paris, , France
Polyclinique Francheville
Périgueux, , France
Hôpital privé des Côtes d'Armor
Plérin, , France
CHU Poitiers
Poitiers, , France
Hôpital privé Claude Galien
Quincy-sous-Sénart, , France
Clinique La Croix Du Sud
Quint-Fonsegrives, , France
CHU Reims
Reims, , France
CHU Rennes - Centre Eugène Marquis
Rennes, , France
CHU Rouen
Rouen, , France
CHU St-Etienne
Saint-Etienne, , France
Clinique Santé Atlantique de Nantes
Saint-Herblain, , France
Clinique Urologique Nantes Atlantis
Saint-Herblain, , France
Clinique Belledonne
Saint-Martin-d'Hères, , France
CHU Strasbourg
Strasbourg, , France
ICANS
Strasbourg, , France
CHU Toulouse - Centre Claudius Régaud
Toulouse, , France
Clinique Pasteur
Toulouse, , France
CHRU Tours
Tours, , France
Institut de Cancérologie lorraine
Vandœuvre-lès-Nancy, , France
Centre Hospitalier de Kourou
Kourou, , French Guiana
CHU Bellepierre
Saint-Denis, , Reunion
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Thierry ROUMEGUERE, Pr
Role: primary
Pierre BIGOT, Pr
Role: primary
Jean-Christophe BERNHARD, Pr
Role: primary
Clément MICHIELS, Dr
Role: primary
Pierre GIMEL, Dr
Role: primary
Xavier TILLOU, Pr
Role: primary
Laurent GUY, Pr
Role: primary
Pietro GRANDE, Dr
Role: primary
Alexandre INGELS, Pr
Role: primary
Benjamin DELATTRE, Dr
Role: primary
Karim BEN OTHMAN, Dr
Role: primary
Constance DEBOUDT-MACE, Dr
Role: primary
Jean-Luc DESCOTES, Pr
Role: primary
Olivier BELAS, Dr
Role: primary
Benjamin ROUGET, Dr
Role: primary
Jonathan OLIVIER, Pr
Role: primary
Charles BALLEREAU, Dr
Role: primary
Aurélien DESCAZEAUD
Role: primary
Philippe PAPAREL, Pr
Role: primary
Eric LECHEVALLIER, Pr
Role: primary
Nicolas BRANGER, Dr
Role: primary
Arnoux VALENTIN, Dr
Role: primary
Jean-Jacques PATARD, Pr
Role: primary
Jérôme GAS, Dr
Role: primary
Pascal ESCHWEGE, Pr
Role: primary
Stéphane DE VERGIE, Dr
Role: primary
Matthieu DURAND, Pr
Role: primary
Alexandre MARSAUD, Dr
Role: primary
Alexis FONTENIL, Dr
Role: primary
Nicolas BRICHART, DR
Role: primary
Sébastien PARIER, Dr
Role: primary
Xavier DURAND, Pr
Role: primary
François AUDENET, Dr
Role: primary
Olivier TRAXER, Pr
Role: primary
Evangelos Xylinas, Dr
Role: primary
Julien ANRACT, Dr
Role: primary
Morgan ROUPRET, Pr
Role: primary
Mostefa BENNAMOUN, Dr
Role: primary
Richard MALLET, Dr
Role: primary
Fabien BOULIERE, Dr
Role: primary
Maxime VALLEE, Dr
Role: primary
Julien DEFONTAINES, Dr
Role: primary
Jean-Baptiste BEAUVAL, Dr
Role: primary
Charlotte JONCOUR, Dr
Role: primary
Karim BENSALAH, Pr
Role: primary
Christian PFISTER, Pr
Role: primary
Lionel BADET, Pr
Role: primary
Quentin-Come LE CLERC, Dr
Role: primary
Lionel HOQUETIS, Dr
Role: primary
Jean-Alexandre LONG, Pr
Role: primary
Hervé LANG, Pr
Role: primary
Gabriel MALOUF, Pr
Role: primary
Nicolas DOUMERC, Dr
Role: primary
Julien GUILLOTREAU, Dr
Role: primary
Franck BRUYERE, Pr
Role: primary
Sophie MARTIN, Dr
Role: primary
Vincent RAVERY, Pr
Role: primary
Davidson SYPRE, Dr
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Binzaqr S, Kryza D, Giraudet AL, Bernhard JC, Gross-Goupil M, Yacoub M, Margue G, Hindie E, Morgat C. Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study). EJNMMI Res. 2025 Apr 9;15(1):38. doi: 10.1186/s13550-025-01232-8.
Ingels A, Bensalah K, Beauval JB, Paparel P, Roupret M, Lang H, Nouhaud FX, Henon F, Bruyere F, Audenet F, Lebacle C, Baumert H, Long JA, Tambwe R, Charles T, Xylinas E, Waeckel T, Michiels C, Asselineau J, Benard A, Margue G, Boissier R, Bigot P, Bernhard JC; Comite Cancer de l'Association Francaise d'Urologie (CCAFU). Comparison of open and robotic-assisted partial nephrectomy approaches using multicentric data (UroCCR-47 study). Sci Rep. 2022 Nov 8;12(1):18981. doi: 10.1038/s41598-022-22912-8.
Morrone A, Bentellis I, Bernhard JC, Bensalah K, Champy C, Bruyere F, Doumerc N, Olivier J, Audenet F, Parier B, Brenier M, Long JA, Nouhaud FX, Branger N, Lang H, Charles T, Xylinas E, Waeckel T, Gomez F, Boissier R, Rouget B, Shaikh A, Chevallier D, Ambrosetti D, Durand M. Positive surgical margin's impact on short-term oncological prognosis after robot-assisted partial nephrectomy (MARGINS study: UroCCR no 96). Sci Rep. 2022 Oct 31;12(1):18342. doi: 10.1038/s41598-022-23146-4.
Brehier G, Bouvier A, Besnier L, Willoteaux S, Nedelcu C, Culty T, Aube C, Bigot P. Renal function after partial nephrectomy following intra-arterial embolization of renal tumors. Sci Rep. 2020 Dec 7;10(1):21352. doi: 10.1038/s41598-020-78461-5.
Related Links
Access external resources that provide additional context or updates about the study.
Program I.Care Bordeaux
UroPredict Algorithm
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHUBX 2011/38
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.